Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, preclinical, and human neuroimaging studies without systematic methodology
PubMed 19319544 · doi:10.1007/s00401-009-0522-3
What was done
Narrative review synthesizing evidence from human neuroimaging, animal models, and molecular studies examining the neurovascular unit and blood-brain barrier (BBB) alterations in Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). The authors summarize mechanisms involving cerebral hypoperfusion, low-density lipoprotein receptor-related protein-1 (LRP-1) expression, apolipoprotein E (ApoE) isoforms, transcription factors myocardin and serum response factor (SRF), and the roles of microglia and perivascular macrophages.
What was found
The abstract provides no quantitative metrics or effect sizes. Qualitatively, it reports that cerebrovascular dysfunction and decreased cerebral blood flow precede cognitive decline and neurodegenerative changes. Reduced flow impairs protein synthesis required for memory and learning, promoting neuritic injury. Early suppression of LRP-1 impairs clearance of amyloid-beta across the BBB, driving vascular accumulation (CAA), vessel wall breakdown, and intracerebral hemorrhages. Myocardin and SRF are highlighted as key transcriptional regulators of vascular responses and LRP-mediated clearance.
Why it matters
This review integrates evidence supporting the neurovascular hypothesis of Alzheimer's disease, arguing that blood-brain barrier failure and vascular dysfunction are early pathogenic contributors rather than mere late-stage consequences of neurodegeneration.
Limits
This is a non-systematic narrative review without formal search methodology, risk-of-bias assessment, or quantitative data synthesis. Much of the detailed molecular mechanistic evidence relies on animal and in vitro models, which may not directly replicate human clinical disease. The abstract reports no human sample sizes or effect estimates.
Cited by
- supports Cerebral amyloid angiopathy (CAA) disrupts cerebral blood vessels.
- supports Vascular dysfunction promotes the formation of amyloid plaques in the brain.